Raised 2026 Adjusted Gross Profit Guidance
Increased full-year 2026 adjusted gross profit guidance from $4M–$6M to $5M–$7M (approximately +20% or +$1M), driven by momentum in DeFi businesses and a $10M public offering.
Strong Adjusted Gross Profit Growth
Q1 adjusted gross profit of ~$960k, up 119% since Q3 and +17% sequentially versus Q4 (Q3: $439k, Q4: $821k, Q1: $960k).
Segment-Level Growth — DeFi Monetization
DeFi monetization generated $245k in Q1 versus $102k in Q4, a +140% quarter-over-quarter increase driven by partnerships (native Markets, Felix Exchange, HIP3 markets, Silhouette testing).
Segment-Level Growth — Yield Enhancement
Yield enhancement strategies generated $211k in Q1 versus $79k in Q4, up +165% quarter-over-quarter, benefiting from HYPE volatility and the formalized Rysk partnership (Rysk premium vault strategies).
Record GAAP Net Income and Adjusted EBITDA Improvement
Q1 net income of $8.8M (record) versus Q4 net loss of $39.8M; Q1 adjusted EBITDA $19.5M versus Q4 adjusted EBITDA negative $38.9M — materially improved profitability driven by treasury gains and accounting presentation of LSTs.
Treasury and Balance Sheet Strengthening
Treasury HYPE holdings exceeded 2M tokens as of May 11; HYPE price rose from 25.4 (end Q4) to 36.6 (Q1) and 42.2 (May 11). HYPE treasury value ~$84.5M vs cash basis $75.9M (+~$8.6M); net asset value rose from $44.2M (Q4) to $69.9M (Q1) to ~ $90M (May 11).
Successful Capital Raise & Cash Position
Closed a $10M public offering (≈2.8M shares, ~$9M net) and additional ATM proceeds; cash, cash equivalents and USDH totaled $9.1M at quarter end and ~$16M as of May 11.
Operational Traction on Hyperliquid and Partnerships
HIP3 markets account for ~50% of Hyperliquid daily average trading activity. HIP4 launched May 2; Hyperliquid's first HIP4 outcome market for Bitcoin had >3x combined volume of Polymarket and Kalshi on launch day. Strategic partner results include Kinetiq >$3.3B total HIP3 volume and $100M+ from a new mobile app in <1 month; HyperLend allocation increased to 10M HPL (1% of supply) enabling borrower rebates.
Improved Cash-Realized Profit Mix and Earnings Multiple
Portion of adjusted gross profit earned in cash expanded from 18% (Q3) to 22% (Q4) to 48% (Q1). Achieved earnings multiple vs base staking yield rose from 1.3x (Q3) to 2.7x (Q4) to 3.1x (Q1).
Path to Cash Flow Breakeven
Company reiterated expectation to achieve operating cash flow breakeven by year-end 2026, supported by growing adjusted gross profit and cost reductions as legacy biotech rolls off.